Afib Flashcards
Things to think about when a patient presents in afib
- Stable or unstable?
- How long have they had it/classification?
- What are contributing factors?
- Evaluation?
- Rate control vs rhythm control?
Pharmacologic & nonpharmacologic approaches to rate/rhythm control?
Evidence of structural or electrical findings further predisposing a patient to AF include?
Atrial enlargement
Frequent atrial ectopy
Short bursts of atrial tachycardia
Atrial flutter
Other high AF risk scenarios
Various Stages of AF prior to permanent AF include?
Paroxysmal AF (3A)
Persistent AF (3B)
Long-standing persistent AF (3C)
Successful AF ablation (3D)
Patient stability, is the patient showing any signs of instability which include?
Acute HF
Hypotension
Worsening angina in pt with CAD
Whats the intervention for unstable AF?
Electrical cardioversion
Clinical manifestations of unstable AF?
Palpitations
CP
Fatigue
Lightheadedness
Dyspnea
Syncope
Asymptomatic
Embolic complication
Exacerbation of HF; most c/o fatigue, lightheadedness, dyspnea, syncope
3 objectives in management of AF include?
rate control
prevention of thromboembolism/stroke
Rhythm correction
What benefits does Rate Control bring?
Improves QOL
Reduces mortality
Decreases risk of cardiomyopathy
Shared decision making-rate v rhythm control
Comparable clinical outcomes in many patients compared to rhythm control
Goals of Rate control
AF w/ no other CVD?
Beta blocker, dilt, verapamil (I)
Amio (IIb)
Goals of Rate control
AF w/ HTN or HFpEF
Beta blocker, dilt, verapamil
Amio
Goals of Rate control
AF w/ LV dysfxn, HF
Beta blocker, digoxin
Amio
Goals of Rate control
AF w/ COPD
Beta blocker, dilt, verapamil
Acute Rate control in AF w/ RVR
Decompensated HF is present give what?
What can cause harm?
IV amio
Verapamil and dilt
Acute Rate control in AF w/ RVR
No decompensated HF is present give what?
Beta blocker, verapamil, dilt
Digoxin
Amio
Goals of Therapy With Rhythm Control
In patients with what condition and persistent AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the problem?
Reduced LV fxn
Patient Factors that Favor Rate Control?
Older
Longer hx of AF
Fewer symptoms
Patient Factors that are variable for Rate vs Rhythm Control?
Age
Antecedent hx of AF
Symptom Burden
Patient Factors that favor Rhythm control?
Younger
Shorter hx of AF
More symptoms
Physical Examination Anatomy that favors rate control?
Easily controlled HR
Larger LA
Less LV dysfxn
Less AV regurgitation
Physical Examination Anatomy that are variable for rate vs rhythm control?
Rate control in AF
LA size
LV fxn in AF
AV regurgitation in AF
Physical Examination Anatomy that favors rhythm control?
Difficult to control HR
Smaller LA
More LV dysfxn
More AV regurgitation
Pharmacologic Cardioversion is usually chosen when?
“…” compared to DC CV is how effective?
“…” is most effective when?
first choice
less effective
in first 7 days
Electrical Cardioversion is recommended in what scenarios?
In patients w/ hemodynamic instability attributable to AF
In patients w/ AF who are hemodynamically stable DC CV can be performed as initial rhythm control strategy or after unsuccessful pharm. CV
Initial Energy delivery chosen for Electrical Cardioversion is what?
200J
Can patients with pacers/ICDs be electrically cardioverted?
yes, but the device will need to be interrogated after CV
What is the risk of thromboembolism events in patients not pre-treated w/ anticoagulation?
~1-7%
Shock failure & immediate recurrence occur in what % of patients?
25%
What can be given in conjunction w/ CV to lower CV threshold, thereby increasing success rate?
Antiarrhythmics
What should the patient receive prior to CV to increase comfort?
conscious sedation or anesthesia
In patients w/ AF duration of >/= 48 hrs what is recommended prior to elective cardioversion?
3 week duration of uninterrupted therapeutic anti-coagulation or imaging evaluation to exclude intracardiac thrombus
In patients w/ AF undergoing cardioversion, therapeutic anticoagulation should be established before cardioversion and continued for how long afterwards w/o interruption to prevent thromboembolism?
4 weeks
In patients w/ AF in whom cardioversion is deferred d/t LAA thrombus detected on pre-cardioversion imaging, therapeutic anticoagulation should be instituted for at least how long? after which imaging should be repeated prior to cardioversion.
3-6 weeks
AF Pharmacologic CV
Normal LV fxn use what?
IV Amio
Ibutilide
Procainimide
AF Pharmacologic CV
HFrEF (LVEF </=40%) use what?
IV Amio
AF Pharmacologic CV
AF occurring outside the hospital in pts w/ normal LV fxn use what?
Flecainide
Propafenone
AF Pharmacologic CV
Normal LV fx , no prior MI or significant structural heart disease use what?
Dofetilide
Dronedarone
Flecainide
Prropafenone
Amio
Sotalol
AF Pharmacologic CV
Prior MI or significant structural heart disease, including HFrEF (LVEF </=40%) use what?
Amio
Dofetilide
Sotalol
Flecainide and Propafenone cause harm
AF Pharmacologic CV
Prior MI or significant structural heart disease, including HFrEF (LVEF </=40%) w/ NYHA FC III or IV or recent decompensated HF use what?
Dronedarone if not
Dont use dronedarone if yes
What is a clinical predictioin rule for estimating risk of stroke in non-rheumatic a-fib?
CHA2DS2-VASc score
CHA2DS2-VASc score
Used to determine whether or not what is required?
antithrombotic threapy
CHA2DS2-VASc score
A high score corresponds to what risk?
greater risk
For patient w/ AF and an estimated annual thromboembolic risk of what? per year (eg CHA2DS2-VASc score of ___ in men and ___ in women), anticoagulation is recommended to prevent stroke and systemic thromboembolism?
> /=2%
/=2
/=3
In patients w/ AF who do not have a hx of moderate to severe rheumatic mitral stenosis or mechanical heart valve, and who are candidates for anticoagulation what are recommended over what to reduce the risk of mortality, stroke, systemic embolism and ICH?
DOACs over warfarin
What is the reversal agent for dabigitran?
idarucizumab
Reversal agents for factor Xa inhibitors are?
andexanet alfa
4 factor-PCC
Reversal agents for warfarin include?
Vitamin K
4 factor-PCC
In patients w/ AF scheduled to Undergo an invasive procedure or surgery the timing of temporary discontinuation of DOACs: Low bleeding risk procedure; High bleeding risk procedure
Apixiban (CrCl > 25mL/min)?
Dabigatran (CrCl > 50mL/min)?
Dabigatran (CrCl 30-50mL/min)?
Edoxaban (CrCl > 15mL/min)?
Rivaroxaban (CrCl > 30mL/min)?
Warfarin?
1d; 2d
1d; 2d
2d; 4d
1d; 2d
1d; 2d
5 d for a target INR < 1.5 and 2-3 d for target INR < 2; 5d
Elderly considerations with AF
AF increases w/?
~ what % of patients w/ AF are > 80y/o?
Consider what when treating?
Symptoms may be?
Risk of CVA is?
Sensitivity to pro-antiarrhythmics effects is?
Rate or Rhythm control is prefered? what is used?
Often more prone to what?
age
35%
co-morbidities
minimal &/or atypical
increased
increased
rate control; BB or CCB
orthostatic hypotension or bradyarrhythmias